A deep plasma workflow applied to discover biomarker candidates of response to chemo-immunotherapy in patients with thoracic malignancies

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide. Although immunotherapy has improved the treatment of NSCLC, a significant number of patients still fail to respond or develop resistance.